Skip to main content
. Author manuscript; available in PMC: 2015 Aug 7.
Published in final edited form as: Cell Signal. 2015 Mar 26;27(8):1666–1675. doi: 10.1016/j.cellsig.2015.03.014

Fig. 5.

Fig. 5

Treatment of wild-type, R38+ and R38− HL-60 with the AhR agonist FICZ. Wild-type (WT), R38+ and R38− were treated for 48 h with RA or RA and the AhR agonist FICZ and analyzed by flow cytometry for (A) CD38 expression, (B) CD11b expression, or (C) G1/G0 cell cycle arrest. Asterisks for p-values of treatment group means compared to control indicate whether p < 0.0001 (****), p < 0.001 (***), p < 0.01 (**) or p < 0.05 (*). FICZ treatment does not significantly rescues (A) CD38 expression, (B) CD11b expression or (C) G1/G0 cell cycle arrest in either RA-resistant cell line.